Get More Information on Autoimmune Disease Therapeutics Market - Request Sample Report
The Autoimmune Disease Therapeutics Market Size was valued at USD 72.34 billion in 2023 and is expected to reach USD 116.81 billion by 2032, growing at a CAGR of 5.52% from 2024-2032.
The Autoimmune Disease Therapeutics Market has been growing steadily, driven by the rising prevalence of autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis. Estimates of the yearly increases in the overall worldwide incidence and prevalence of autoimmune diseases are 19.1% and 12.5%, respectively, according to the National Institutes of Health. This increasing prevalence has heightened the need for more effective and targeted treatment options, significantly advancing therapeutic approaches. Among these advancements, biologics and biosimilars have emerged as transformative solutions, offering more precise mechanisms of action compared to traditional treatments and improving patient outcomes significantly.
Demand for autoimmune disease therapeutics is being driven by rising healthcare spending, which is increasing investment in advanced treatment options. The NIH’s investment in autoimmune disease research has also grown significantly, rising from USD 800 million to over USD 1 billion in fiscal year 2022. This surge in funding has facilitated the widespread adoption of biologics, such as monoclonal antibodies and JAK inhibitors, which are becoming primary treatments for many autoimmune conditions. As a result, patients and healthcare providers are seeking therapies that not only offer immediate symptom relief but also provide long-term remission, improving quality of life. The availability of these advanced immunomodulators has created a competitive market, while government initiatives and increased R&D investments are addressing unmet needs and enhancing accessibility, further expanding market growth.
Looking ahead, the autoimmune disease therapeutics market is poised for significant growth, driven by innovations in artificial intelligence and precision medicine. In May 2024, researchers at Penn State developed a new AI algorithm, EXPRESSO, to improve the prediction and treatment of autoimmune diseases, further enhancing drug development and patient management. These technologies are expected to pave the way for more targeted treatments and personalized strategies, advancing precision medicine. Breakthroughs in gene therapy and novel delivery mechanisms also offer transformative potential, reshaping treatment paradigms and ensuring better disease control and improved quality of life for patients.
DRIVERS
Advancements in Biotechnology Fuel the Growth of the Autoimmune Disease Therapeutics Market
The development of monoclonal antibodies, biologics, and gene therapies has transformed the landscape of autoimmune disease management, offering more targeted and effective treatment options. These advanced therapies specifically target the underlying mechanisms of diseases, providing better outcomes compared to traditional treatments. Biologics, in particular, have emerged as the cornerstone of autoimmune disease treatment, offering improved efficacy and fewer side effects. Additionally, the growing focus on gene therapies and personalized medicine holds great promise for future treatment advancements. These innovations are not only improving patient outcomes but are also expanding market opportunities for biotech and pharmaceutical companies globally, contributing to the rapid expansion of the autoimmune disease therapeutics market.
Emergence of Personalized Medicine Enhances Autoimmune Disease Therapeutics Market Growth
The rise of personalized and precision medicine is revolutionizing the autoimmune disease therapeutics market by offering tailored treatments based on an individual’s unique genetic makeup and disease profile. This approach allows for more targeted therapies, improving treatment effectiveness and minimizing side effects, which significantly enhances patient outcomes. By analyzing genetic, environmental, and lifestyle factors, healthcare providers can create customized treatment plans that address the root causes of autoimmune conditions. As the demand for more efficient, patient-specific therapies grows, pharmaceutical companies are increasingly investing in personalized medicine, driving innovation and market expansion. This shift towards individualized care is helping to optimize therapeutic efficacy, reduce healthcare costs, and boost the overall growth of the autoimmune disease therapeutics market, creating vast opportunities for both research and commercialization.
RESTRAINTS
Side Effects and Safety Concerns Hinder Growth of Autoimmune Disease Therapeutics Market
Biologic and immunosuppressive therapies, while highly effective in treating autoimmune diseases, come with notable risks that can influence patient decisions and market growth. These advanced treatments often carry side effects such as increased susceptibility to infections, organ damage, and allergic reactions. For instance, biologics can suppress the immune system, leaving patients more vulnerable to opportunistic infections, while the prolonged use of immunosuppressive drugs can result in complications like liver damage. These safety concerns may lead to patients avoiding or discontinuing treatment, particularly when safer, more traditional options are available. Furthermore, the need for regular monitoring to manage these risks adds a burden on healthcare systems, limiting the widespread adoption and growth of these therapies in the autoimmune disease market.
BY SALES CHANNEL
The Hospital Pharmacy segment led the Autoimmune Disease Therapeutics Market in 2023, capturing approximately 54% of the revenue share. This dominance is driven by the critical role hospitals play in managing complex autoimmune treatments, where specialized therapies like biologics and immunosuppressants are administered. Additionally, hospitals provide direct access to healthcare professionals and monitoring, ensuring optimal patient care. This makes the hospital setting the preferred choice for advanced autoimmune disease therapies.
The Online Store segment is expected to grow at the fastest CAGR of 8.04% from 2024 to 2032. The growth is fueled by the increasing shift toward e-commerce, offering convenient access to autoimmune therapeutics. Telemedicine’s rise and the growing preference for home delivery of medications have boosted online pharmacy sales. As digital healthcare solutions expand, more patients are turning to online stores for their treatment needs.
BY INDICATION
The Rheumatic Disease segment led the Autoimmune Disease Therapeutics Market in 2023, capturing around 43% of the revenue share. This dominance is driven by the high prevalence of rheumatoid arthritis and other rheumatic conditions. The growing demand for advanced biologics and disease-modifying antirheumatic drugs has solidified its position. Additionally, ongoing innovations in targeted therapies have further strengthened this segment's market leadership.
The Inflammatory Bowel Disease segment is expected to grow at the fastest CAGR of 8.99% from 2024 to 2032. This growth is fueled by the rising incidence of Crohn’s disease and ulcerative colitis, alongside increasing demand for biologic therapies. Advances in personalized medicine and early diagnosis are enhancing treatment effectiveness, making IBD the fastest-growing segment in the autoimmune therapeutics market.
BY DRUG CLASS TYPE
The Anti-inflammatory segment dominated the Autoimmune Disease Therapeutics Market in 2023, holding the highest revenue share of approximately 43%, and is expected to grow at the fastest CAGR of about 8.99% from 2024 to 2032. This dominance is driven by the widespread use of anti-inflammatory drugs, particularly corticosteroids, non-steroidal anti-inflammatory drugs, and biologics, which are essential in managing autoimmune conditions like rheumatoid arthritis, psoriasis, and lupus. As the global prevalence of these diseases continues to rise, the demand for effective anti-inflammatory treatments is increasing. Moreover, ongoing advancements in biological therapies and the development of targeted anti-inflammatory drugs are driving the segment's robust growth, positioning it for continued expansion in the coming years.
North America dominated the Autoimmune Disease Therapeutics Market in 2023, capturing approximately 44% of the revenue share. This dominance is primarily attributed to the high prevalence of autoimmune diseases, advanced healthcare infrastructure, and strong reimbursement policies in the region. The presence of leading pharmaceutical companies, extensive research and development efforts, and the adoption of cutting-edge biologic therapies further solidify North America's market leadership.
In contrast, the Asia Pacific region is expected to grow at the fastest CAGR of 7.25% from 2024 to 2032. This growth is driven by the increasing incidence of autoimmune diseases and improving healthcare access across emerging economies. Rising awareness, enhanced diagnostic capabilities, and the growing adoption of biologics and personalized treatments are contributing to the rapid market expansion in the region. As healthcare infrastructure continues to improve, Asia Pacific is positioned to become a key growth driver in the autoimmune disease therapeutics market.
In 2024, Bristol Myers Squibb is advancing CAR T-cell therapy for autoimmune diseases like lupus and multiple sclerosis, with an emphasis on providing innovative, long-term treatment options beyond current therapies, including the potential to "reset" the immune system
In September 2024, Novartis announced that Kesimpta® (ofatumumab) showed long-term benefits for relapsing multiple sclerosis (RMS) patients, with nearly 90% of first-line patients experiencing no disability progression for up to six years, emphasizing the advantages of early treatment.
Pfizer Inc. (Xeljanz, Enbrel)
Bristol-Myers Squibb Company (Orencia, Zeposia)
F. Hoffmann-La Roche Ltd. (Genentech, Inc.) (Actemra, Rituxan)
Novartis AG (Cosentyx, Ilaris)
Abbott Laboratories (Humira [pre-spin-off], FreeStyle Libre)
AbbVie Inc. (Humira, Rinvoq)
Amgen Inc. (Enbrel, Otezla)
Johnson & Johnson (Remicade, Stelara)
AstraZeneca Plc (Saphnelo, Fasenra)
UCB S.A. (Cimzia, Keppra)
Biogen Idec Inc. (Tysabri, Tecfidera)
Chugai Pharmaceutical Co. Ltd. (Actemra, Enspryng)
Danaher (Molecular Diagnostic Tools, Clinical Research Equipment)
Bayer Schering Pharma AG (Betaseron, Eylea)
Elan Corporation Plc (Tysabri, Prialt)
Eli Lilly and Company (Olumiant, Taltz)
GlaxoSmithKline Plc (Benlysta, Nucala)
HYCOR Biomedical (Allergy Testing Systems, Immunoassay Solutions)
Merck & Co. Inc. (Simponi, Keytruda)
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 72.34 Billion |
| Market Size by 2032 | USD 116.81 Billion |
| CAGR | CAGR of 5.52% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drug Class (Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons, Others) • By Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, Other Indications) • By Sales Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Store) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Pfizer Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Novartis AG, Abbott Laboratories, AbbVie Inc., Amgen Inc., Johnson & Johnson, AstraZeneca Plc, UCB S.A., Biogen Idec Inc., Chugai Pharmaceutical Co. Ltd., Danaher, Bayer Schering Pharma AG, Elan Corporation Plc, Eli Lilly and Company, GlaxoSmithKline Plc, HYCOR Biomedical, Merck & Co. Inc. |
| Key Drivers | • Advancements in Biotechnology Fuel the Growth of the Autoimmune Disease Therapeutics Market. • Emergence of Personalized Medicine Enhances Autoimmune Disease Therapeutics Market Growth |
| RESTRAINTS | • Side Effects and Safety Concerns Hinder Growth of Autoimmune Disease Therapeutics Market |
Ans: Autoimmune Disease Therapeutics Market was valued at USD 72.34 billion in 2023 and is expected to reach USD 116.81 billion by 2032, growing at a CAGR of 5.52% from 2024-2032
Ans: North America dominates due to its high prevalence and advanced healthcare infrastructure.
Ans: Hospital pharmacies dominate the market, capturing about 54% of revenue share in 2023.
Ans: The Rheumatic Disease segment holds the largest market share in the autoimmune disease therapeutics market, capturing approximately 43% of the revenue share in 2023.
Ans: The Asia Pacific region is expected to grow at the highest CAGR of 7.25% from 2024 to 2032
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Autoimmune Disease Therapeutics Market Segmentation, by Indication
7.1 Chapter Overview
7.2 Rheumatic Disease
7.2.1 Rheumatic Disease Market Trends Analysis (2020-2032)
7.2.2 Rheumatic Disease Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Type 1 Diabetes
7.3.1 Type 1 Diabetes Market Trends Analysis (2020-2032)
7.3.2 Type 1 Diabetes Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Multiple Sclerosis
7.4.1 Multiple Sclerosis Market Trends Analysis (2020-2032)
7.4.2 Multiple Sclerosis Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Inflammatory Bowel Disease
7.5.1 Inflammatory Bowel Disease Market Trends Analysis (2020-2032)
7.5.2 Inflammatory Bowel Disease Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Other Indications
7.6.1 Other Indications Market Trends Analysis (2020-2032)
7.6.2 Other Indications Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Autoimmune Disease Therapeutics Market Segmentation, by Drug Class Type
8.1 Chapter Overview
8.2 Anti-inflammatory
8.2.1 Anti-inflammatory Market Trends Analysis (2020-2032)
8.2.2 Anti-inflammatory Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Antihyperglycemics
8.3.1 Antihyperglycemics Market Trends Analysis (2020-2032)
8.3.2 Antihyperglycemics Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 NSAIDs
8.4.1 NSAIDs Market Trends Analysis (2020-2032)
8.4.2 NSAIDs Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Interferons
8.5.1 Interferons Market Trends Analysis (2020-2032)
8.5.2 Interferons Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Others
8.6.1 Others Market Trends Analysis (2020-2032)
8.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Autoimmune Disease Therapeutics Market Segmentation, by Sales Channel
9.1 Chapter Overview
9.2 Hospital Pharmacy
9.2.1 Hospital Pharmacy Market Trends Analysis (2020-2032)
9.2.2 Hospital Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Drug Store & Retail Pharmacy
9.3.1 Drug Store & Retail Pharmacy Market Trends Analysis (2020-2032)
9.3.2 Drug Store & Retail Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Online Store
9.4.1 Online Store Market Trends Analysis (2020-2032)
9.4.2 Online Store Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.2.4 North America Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.2.5 North America Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.2.6.2 USA Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.2.6.3 USA Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.2.7.2 Canada Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.2.7.3 Canada Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.2.8.2 Mexico Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.2.8.3 Mexico Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.6.2 Poland Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.1.6.3 Poland Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.7.2 Romania Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.1.7.3 Romania Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.4 Western Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.2.5 Western Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.6.2 Germany Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.2.6.3 Germany Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.7.2 France Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.2.7.3 France Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.8.2 UK Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.2.8.3 UK Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.9.2 Italy Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.2.9.3 Italy Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.10.2 Spain Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.2.10.3 Spain Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.13.2 Austria Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.2.13.3 Austria Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.4 Asia Pacific Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.4.5 Asia Pacific Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.6.2 China Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.4.6.3 China Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.7.2 India Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.4.7.3 India Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.8.2 Japan Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.4.8.3 Japan Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.9.2 South Korea Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.4.9.3 South Korea Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.10.2 Vietnam Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.4.10.3 Vietnam Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.11.2 Singapore Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.4.11.3 Singapore Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.12.2 Australia Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.4.12.3 Australia Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.4 Middle East Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.5.1.5 Middle East Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.6.2 UAE Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.5.1.6.3 UAE Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.2.4 Africa Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.5.2.5 Africa Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.4 Latin America Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.6.5 Latin America Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.6.2 Brazil Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.6.6.3 Brazil Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.7.2 Argentina Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.6.7.3 Argentina Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.8.2 Colombia Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.6.8.3 Colombia Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Drug Class Type (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Autoimmune Disease Therapeutics Market Estimates and Forecasts, by Sales Channel (2020-2032) (USD Billion)
11. Company Profiles
11.1 Pfizer Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Bristol-Myers Squibb Company
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Novartis AG
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Abbott Laboratories
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 AbbVie Inc.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Amgen Inc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Johnson & Johnson
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 AstraZeneca Plc
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 UCB S.A.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusio
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Drug Class Type
Anti-inflammatory
Antihyperglycemics
NSAIDs
Interferons
Others
By Indication
Rheumatic Disease
Type 1 Diabetes
Multiple Sclerosis
Inflammatory Bowel Disease
Other Indications
By Sales Channel
Hospital Pharmacy
Drug Store & Retail Pharmacy
Online Store
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)